Share

Financial news - May 2023 - news published 76.217 - readings 1.013.702

Select company / Select period
Deutsche Post DHL

Deutsche Post DHL

Over 16,000 customers enabled to tackle uncertainties in logistics through DHL Global Forwarding's digital platform myDHLi

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Deutsche Post AG published this content on 10 May 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 May 2023 11:12:30 UTC .

Continue reading
10.05.2023
Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc.

Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No ...

Continue reading
10.05.2023
Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc.

Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ...

Continue reading
10.05.2023
Bicycle Therapeutics plc

Bicycle Therapeutics plc

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology - Form 8-K

Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology · Collaboration will leverage Bicycle Therapeutic's synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology · Advancing the use of bicycle peptides as a novel targeting approach in radio ...

Continue reading
10.05.2023
Acorda Therapeutics Inc.

Acorda Therapeutics Inc.

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture. Under the terms of the Indenture, Acorda may elect to make interest payments under the Indenture in cash or shares of the Company's common ...

Continue reading
10.05.2023
Bio-Techne Corporation

Bio-Techne Corporation

BIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNA

MINNEAPOLIS , May 10, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents (ASRs) for the detection of immunoglobulin kappa a ...

Continue reading
10.05.2023
Seritage Growth Properties

Seritage Growth Properties

Quarterly Report for Quarter Ending MARCH 31, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission Fil ...

Continue reading
10.05.2023